Dana-Farber Cancer Institute Inflammatory Breast Cancer Program

About

Dana-Farber Cancer Institute (DCFI) is a principal teaching affiliate of Harvard Medical School and a founding member of the Dana-Farber/Harvard Cancer Center, a federally designated comprehensive cancer center. Today, the Institute is involved in some 900 clinical trials and internationally renowned for its blending of research and clinical excellence. Providing advanced training in cancer treatment and research for an international faculty, the Institute conducts community-based programs in cancer prevention, detection and control throughout New England, and maintains joint programs with other Boston institutions affiliated with Harvard Medical School and the Partners Health Care System. The dedicated Inflammatory Breast Cancer Program at DFCI has three core aims: treatment, research and education. As a leader in IBC care, the Dana-Farber clinical team uses their extensive experience in multiple disciplines to design and implement an individual treatment plan targeted to a patient’s specific disease. Physician-scientists of the IBC Program focus on IBC-specific clinical trial development and lead research efforts that are increasing understanding of the unique biology of IBC, which is essential to advancing knowledge of this rare disease and create new options for treatment. Learn more about the Inflammatory Breast Cancer Program at Dana-Farber Cancer Institute >